Introduction
============

The availability and the extensive use of tyrosine kinase inhibitors targeting the BCR-ABL protein in patients with chronic myeloid leukemia (CML) has reduced the rate of progression from chronic phase to advanced phase.^[@b1-1021530]^ As a consequence, at least 50% of deaths occur in patients in chronic phase, or in remission,^[@b2-1021530]^ raising concerns on the relationship of such deaths with the off-target effects of tyrosine kinase inhibitors.^[@b3-1021530]^ Although most of the attention is focused on cardiovascular adverse events,^[@b4-1021530]^ other malignancies are the most common cause of death in patients in chronic phase or in remission.^[@b2-1021530]^

Imatinib was the first tyrosine kinase inhibitor developed for the treatment of CML and is the most extensively studied. However, it is still unclear whether its immunomodulatory properties^[@b5-1021530]--[@b11-1021530]^ may affect anti-cancer immune surveillance in the long-term, or whether its off-target activity may influence oncosuppressive pathways. Of note, regardless of the underlying mechanisms, neoplastic alterations have been described in multiple tissues of rats exposed to imatinib.^[@b12-1021530]^ Several studies, mainly referring to imatinib-treated patients, have investigated the risk of second primary malignancy (SPM) in CML,^[@b13-1021530]--[@b20-1021530]^ with sometimes contrasting results. Indeed, in comparisons with the general population, some epidemiological studies of unselected CML patients reported higher incidences of SPM^[@b18-1021530],[@b21-1021530]^ while similar incidences were found in three large analyses of patients enrolled in clinical trials.^[@b14-1021530],[@b17-1021530],[@b20-1021530]^

Moreover, it is still debated whether CML patients *per se*, regardless of the treatment used, might be at higher risk of SPM,^[@b21-1021530]--[@b24-1021530]^ a condition that might be now unveiled by the increased survival of patients.

For all these reasons, it is important to retrieve additional data on the potential carcinogenic role of tyrosine kinase inhibitors,^[@b12-1021530]^ on the incidence of other malignancies, and on their outcome.^[@b13-1021530]--[@b20-1021530]^

We report here on the malignancies observed in a cohort of 514 evaluable patients with newly diagnosed, chronic phase CML, treated first-line with imatinib in three multicenter national studies.

Methods
=======

We performed a retrospective analysis of 559 patients enrolled in three prospective clinical trials with imatinib front-line in 62 Italian institutions of the *Gruppo Italiano Malattie Ematologiche dell'Adulto* (GIMEMA) CML Working Party. Detailed inclusion criteria have been published previously.^[@b25-1021530]--[@b28-1021530]^ Briefly, patients were at least 18 years old, with a diagnosis of Philadelphia chromosome/*BCR-ABL*-positive CML in early chronic phase (6 months or less from diagnosis to starting imatinib; only hydroxyurea allowed). All the patients provided written informed consent before enrollment. The studies were reviewed and approved by the Internal Review Board of all the participating Institutions, and performed in accordance with the Declaration of Helsinki. For the purpose of the present analysis, a specific survey was conducted in all Centers with a request to review the clinical records of all the enrolled patients. Overall, 52/62 (84%) Institutions replied to the survey, and each Center reported on all its patients; overall, data were collected on 514/559 (92%) patients, 309 (60%) males and 205 (40%) females. Detailed data on all malignancies, prior to and after the diagnosis of CML, were collected, including: site, histology type, date of diagnosis, therapy (surgery, chemotherapy, radiotherapy, other), and outcome. Cancers were classified according to the International Classification of Diseases, version 10 (ICD-10). We excluded non-melanoma skin cancers (ICD-10: C-44) from the analysis, because of the possible under-reporting of such neoplasms, and acute leukemias/myelodysplastic syndromes, considering their possible relationship with CML.

Prior malignancies were defined as malignancies diagnosed before CML, other malignancies denote all malignancies, including relapses of prior malignancies, diagnosed after CML. SPM, the focus of this analysis, are *de novo* malignancies diagnosed after CML (thus excluding relapses of prior malignancies).

Descriptive statistics were used for SPM incidence and mortality. Means were compared with the *t*-test and frequencies with the χ^2^ test or Fisher exact test, as appropriate. Cumulative incidences and survival curves were estimated according to the Kaplan-Meier method. For comparison with the general population, we calculated the standardized incidence ratio (SIR) and standardized mortality ratio (SMR), which are based on the ratio between observed cases and expected cases in the general reference population in the same period, matched by sex and age (5-year age classes were considered). We reported the overall ratios (for subjects aged 20--84 years), rather than those for specific age subgroups, to avoid selection biases.

Data on cancer incidence and mortality in the general Italian population were taken in March 2016 from the AIRTUM (*Associazione Italiana Registri TUMori*) database ITACAN (AIRTUM ITACAN: *Tumori in Italia*, Versione 2.0; <http://www.registri-tumori.it>), which covers 51% of the Italian general population, and reports cancer incidence and mortality rates derived from real, observed cancer cases. Times to events (patient-years) were calculated from the date of diagnosis of CML to the date of diagnosis of the SPM, death, or last contact, whichever came first, for incidence; and to the date of death or last contact, for mortality.

Results
=======

Patients
--------

Data from 514 patients, 309 (60%) males and 205 (40%) females, were analyzed. The median age at CML diagnosis was 52 (range, 18--84) years. The median follow-up from diagnosis of CML to death, or last contact, whichever came first, was 74 (range, 3--99) months. The total patient-years for the incidence calculation were 3011.1 (males and females: 1806.3 and 1204.8 patient-years, respectively). The total patient-years for the mortality calculation were 3077.7 (males and females: 1849.4 and 1228.3 patient-years, respectively). The characteristics of the whole cohort of patients and of patients with or without SPM are summarized in [Table 1](#t1-1021530){ref-type="table"}; age at CML diagnosis was significantly higher in patients with SPM than in patients without SPM (60 and 51 years, respectively; *P*=0.002).

###### 

Characteristics of the patients at diagnosis of chronic myeloid leukemia.

![](1021530.tab1)

Malignancies in the follow-up
-----------------------------

Overall, other malignancies were observed in 35/514 (6.8%) patients ([Tables 2](#t2-1021530){ref-type="table"} and [3](#t3-1021530){ref-type="table"}). Four patients had a relapse of a malignancy diagnosed before CML (2 bladder cancers, 1 renal cancer, and 1 breast cancer), and another patient developed multiple myeloma from a pre-existing monoclonal gammopathy of undetermined significance. SPM were, therefore, diagnosed in 30/514 (5.8%) patients (17/309 males, 5.5%; 13/205, 6.2%, females). The estimated 7-year cumulative incidence of SPM was 6.3% and 8.5% in males and females, respectively ([Figure 1A](#f1-1021530){ref-type="fig"}). In these patients, the median time from CML diagnosis to SPM diagnosis was 34 (range, 3--80) months, and the median age at SPM diagnosis was 65 (range, 38--79) years. The most frequent SPM were colon cancers (n=4), prostate cancers (n=3), breast cancers (n=2), central nervous system cancers (n=2), pancreatic cancers (n=2), liver cancers (n=2), non-Hodgkin lymphomas (n=2), and thyroid cancers (n=2). No difference in the incidence of SPM was observed between patients initially treated with high-dose imatinib (800 mg) *versus* standard-dose imatinib (400 mg): 9/126 (7.1%) *versus* 21/388 (5.4%), respectively (*P*=0.51); moreover, no patient with SPM received treatment with second-generation tyrosine kinase inhibitors or underwent allogeneic stem cell transplantation. At the time of SPM diagnosis, all patients were in complete hematologic remission, 28/30 were in complete cytogenetic remission and 27/30 had a major molecular response.

###### 

Malignancies observed in the follow-up and related mortality.
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###### 

Details of malignancies observed during the follow-up of patients with chronic myeloid leukemia.
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![Cumulative incidence of second primary malignancies and overall survival of patients with or without second primary malignancies. (A) Cumulative incidence of SPM in 514 patients (309 males; 205 females); the estimated 7-year cumulative incidence was 6.3% and 8.5% in males and females, respectively; (B) Overall survival (OS) from CML diagnosis: 7-year OS was 43.6% in patients with SPM (n=30) and 89.9% in patients without SPM (n=484); *P*\<0.001. (C) OS from SPM diagnosis (n=30): the median OS was 18 months, and the estimated 4-year OS was 42.3%](1021530.fig1){#f1-1021530}

Other malignancies were the second cause of death in this cohort (19/514; 3.7%), while death from progression of CML to advanced phase was the first cause (25/514; 4.8%). As expected, patients who developed a SPM had a significantly lower overall survival rate compared to patients without a SPM (7-year overall survival: 43.6% *versus* 89.9%; *P*\<0.001; [Figure 1B](#f1-1021530){ref-type="fig"}). In detail, considering only the patients with SPM, 16/30 (53%) died because of the SPM. The median overall survival after diagnosis of the SPM was 18 months ([Figure 1C](#f1-1021530){ref-type="fig"}) and the median age at death of patients with these malignancies was 66 (range, 53--84) years. All four patients with colon cancer died within 2 years of diagnosis (after 1, 5, 6, and 24 months).

Comparison with the general population
--------------------------------------

We then compared the incidence of SPM, and the related mortality, with that reported in the Italian general population, matched by sex and age ([Table 4](#t4-1021530){ref-type="table"}).

###### 

Second primary malignancies: comparison of incidence and mortality with those in the Italian general population, matched by sex and age\*.

![](1021530.tab4)

In Italy, the standardized incidence of malignancy between 20 and 84 years of age is 7.6/1.000 and 5.2/1.000 person-years in males and females, respectively. In males, we observed 17 SPM, and the SIR was 1.06 \[95% confidence interval (CI): 0.57 -- 1.54\]. In females, we observed 13 SPM, which resulted in a SIR of 1.61 (95% CI: 0.92 -- 2.31).

In Italy, the standardized mortality for malignancy between 20 and 84 years of age is 3.5/1.000 and 1.9/1.000 person-years in males and females, respectively. In our cohort, 9/309 (2.9%) males died of a SPM, and the SMR was 1.26 (95% CI: 0.53 -- 1.99); 7/205 (3.4%) females died of a SPM, resulting in a statistically significantly higher SMR (2.41; 95% CI: 1.26 -- 3.56).

Discussion
==========

The assessment of SPM risk is particularly complex: large cohorts of patients, long follow-up, accurate and comprehensive data collection, and a proper reference population are required for a good estimation of the risk. In this context, the analysis of both clinical trials and epidemiological registries, although with distinct drawbacks, provides essential information.

In our cohort of 514 patients with chronic phase CML treated in clinical trials with front-line imatinib, with a median follow-up of 74 months, 30 (5.8%) patients had a SPM. A higher age at CML diagnosis was the only baseline factor significantly associated with SPM; reasonably, it justifies the higher proportion of intermediate-Sokal risk patients observed in this group. Of note, no CML-related characteristic was linked to the occurrence of SPM.

The incidence of SPM among patients with chronic phase CML was not significantly increased compared to that in the age- and sex-matched Italian population. These data confirm the main findings of three large analyses of CML patients treated with tyrosine kinase inhibitors in clinical trials (German CML study IV,^[@b20-1021530]^ MD Anderson Cancer Center trial,^[@b17-1021530]^ and Novartis global database^[@b14-1021530]^) in which the overall incidence of SPM was similar to that of the general population. Of note, this conclusion was consistent despite the important differences of these studies regarding patients' characteristics (including epidemiological aspects), treatments received, and follow-up. Two of these analyses found higher SIR for some cancers types: non-Hodgkin lymphomas in the German CML study IV;^[@b20-1021530]^ melanoma, kidney and endocrine tumors in the MD Anderson Cancer Center analysis.^[@b17-1021530]^ Unfortunately, in our study, the relatively low number and the heterogeneity of the malignancies observed precluded a proper evaluation of the SIR for different types of cancer.

In contrast to these data, analysis of the epidemiological CML Swedish Registry on 868 unselected CML patients treated with tyrosine kinase inhibitors^[@b18-1021530]^ showed an overall increased SIR for other malignancies (1.52; 95% CI: 1.13 -- 1.99); the SIR maintained a statistical significance in females (1.81; 95% CI: 1.18 -- 2.66). It is worth noting that we observed a trend for an increased SIR in females (1.6; lower 95% CI: 0.92).

In our study, progression of CML to advanced phase and other malignancies were the most common causes of death (4.8 and 3.7%, respectively). The death rate in patients with SPM was particularly high (53%), with a relatively short median overall survival (18 months from diagnosis of the SPM). Of note, in females, the mortality from SPM was significantly superior to that expected in the Italian age-matched female population, with a SMR of 2.41 (95% CI: 1.26 -- 3.56).

Despite the limitations due to the small number of patients, some factors favoring the high mortality observed for SPM can be hypothesized. For example, the therapeutic approach to SPM in patients with CML may be less intensive (6/30 patients received only palliative care) or the biological behavior of the SPM may be more aggressive, as a consequence of CML itself, or because of imatinib. With regards to the latter point, it should be remembered that in a breast cancer model in mice, treatment with imatinib was associated with an increased malignant behavior compared to control conditons.^[@b29-1021530]^ Moreover, tyrosine kinase inhibitors could enhance, or facilitate, the progression of SPM through the inhibition of ABL, which is a downstream effector of the epinephrine receptors that might have a tumor-suppressor role in breast, prostate, and colorectal cancers^[@b30-1021530]--[@b32-1021530]^ (interestingly, all our patients with a colon cancer died) or through impairment of the immune system,^[@b6-1021530]--[@b11-1021530]^ potentially affecting anti-tumor surveillance. An in-depth evaluation of immunological mechanisms might be particularly intriguing in view of the potential use of new molecules enhancing the immune system against cancer.

In conclusion, the prevalence of CML is increasing steadily and this, together with the aging of patients, means that the number of subjects at risk of developing SPM is increasing. However, the fact that an increased incidence was not detectable in the majority of the cohorts analyzed so far does not support the fear that chronic treatment with tyrosine kinase inhibitors, in particular imatinib, cause more SPM compared to those occurring in the general population. Despite these reassuring results, large studies with a long follow-up (e.g. using data from CML registries) are warranted to properly investigate the incidence of specific types of SPM, and to fully address mortality due to SPM. This could help to improve patients' management through early diagnosis of SPM and treatment optimization in conjunction with oncologists. Furthermore, the comparison of the incidence of SPM (and their outcomes) in patients treated with different tyrosine kinase inhibitors may provide important clues on the potential role of each inhibitor.
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